Recent advances in the pharmacological management of hypercholesterolaemia

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 5, 2016, Pages 436-446

  Ajufo, Ezim ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANACETRAPIB; ATORVASTATIN; BEMPEDOIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EVOLOCUMAB; EZETIMIBE; GEMCABENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MBX 8025; MIPOMERSEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KUXIN TYPE 9; SERINE PROTEINASE; SIMVASTATIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GENE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LDLR GENE; LIVER TOXICITY; MTTP GENE; MYALGIA; NAUSEA; NPC1L1 GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; REVIEW; RISK REDUCTION; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BLOOD;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; EZETIMIBE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; PROPROTEIN CONVERTASE 9;

EID: 84962178022     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)00074-7     Document Type: Review

References (99)

1. Andersson C, Lyass A, Vasan RS, et al. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J 2014, 168:878. 83.e1.
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
3. Ference B, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol 2012, 60:2631-2639.
4. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015, 65:1552-1561.
5. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
6. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1438-1443.
7. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
8. Carlson LA, Rosenhamer G Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
10. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374. The Lipid Research Clinics Coronary Primary Prevention Trial Results: II.
11. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174000 participants in 27 randomised trials. Lancet 2015, 385:1397-1405. Cholesterol Treatment Trialists' (CTT) Collaboration.
12. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014, 64:485-494.
13. Ooi CP, Loke SC Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 2014, 31:2-14.
14. Mancini GBJ, Hegele RA, Leiter LA Dyslipidemia. Can J Diabetes 2013, 37(suppl 1):S110-S116.
15. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm. Endocr Pract 2015, 21:438-447.
16. Sandhu S, Moosavi M, Golmohammadi K, Francis GA Colesevelam as an add-on treatment for control of dyslipidemia and hyperglycemia in type 2 diabetes. Can J Diabetes 2015, published online Nov 12. 10.1016/j.jcjd.2015.07.008.
17. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015, 372:2387-2397.
18. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
19. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
20. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
21. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2015, 36:566-575.
22. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015, 36:2996-5003.
23. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1489-1499.
24. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385:331-340.
25. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2531-2540.
26. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014, 311:1870-1882.
27. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1500-1509.
28. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385:341-350.
29. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
30. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
31. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
32. Stitziel NO, Won H-H, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014, 371:2072-2082.
33. Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome European Society of Cardiology, (accessed Feb 20, 2016). http://www.escardio.org/The-ESC/Press-Office/Press-releases/Last-5-years/ezetimibe-reduces-cardiovascular-events-in-diabetics-with-recent-acute-coronary-syndrome.
34. Urban D, Poss J, Bohm M, Laufs U Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013, 62:1401-1408.
35. Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
36. Maxwell KN, Breslow JL Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004, 101:7100-7105.
37. Maxwell KN, Fisher EA, Breslow JL Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 2005, 102:2069-2074.
38. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006, 15:1551-1558.
39. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
40. Horton JD, Cohen JC, Hobbs HH Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
41. Bergeron N, Phan BAP, Ding Y, Fong A, Krauss RM Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015, 132:1648-1666.
42. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
43. Mearns BM Dyslipidaemia: promising results for TA-8995 in TULIP. Nat Rev Cardiol 2015, 12:443.
44. Kastelein JJP, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015, 385:2153-2161.
45. Miyosawa K, Singh S, Watanabe Y, et al. Abstract 16404: CETP inhibitor K-312 lowers PCSK9 expression and LDL cholesterol levels in vivo. Circulation 2014, 130:A16404.
46. Miyosawa K, Watanabe Y, Murakami K, et al. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J Physiol Endocrinol Metab 2015, 309:E177-E190.
47. Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 2015, 9:295-304.
48. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013, 62:1154-1162.
49. Bays HE, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 2003, 92:538-543.
50. Bays HE, Schwartz S, Littlejohn T, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011, 96:2889-2897.
51. Catabasis Pharmaceuticals announces preliminary phase 1 data for hypercholesterolemia product candidate CAT-2054 Catabasis, (accessed Feb 20, 2016). http://www.catabasis.com/pdfs/Catabasis-CAT-2054-101%20FINAL%20060415.pdf.
52. Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 2013, 230:373-380.
53. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015, 115:1212-1221.
54. Fitzgerald K, Simon A, White S, et al. ALN-PCSsc, an RNAi investigational agent that inhibits PCSK9 synthesis with the potential for effective bi-annual dosing: interim results (accessed Feb 20, 2016). https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_479191.pdf.
55. Stein EA, Kasichayanula S, Turner T, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol 2014, 63:A1372.
56. Galabova G, Brunner S, Winsauer G, et al. Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management. PLoS One 2014, 9:e114469.
57. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015, 56:1308-1317.
58. Reiner Z Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015, 12:565-575.
59. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29:2625-2633.
60. Beliard S, Carreau V, Carrie A, et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis 2014, 234:136-141.
61. Ginsberg HN, Rader DJ, Raal FJ, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia (accessed Feb 20, 2016). https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469616.pdf.
62. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition. Circulation 2012, 126:2408-2417.
63. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014, 35:2146-2157.
64. Goldstein JL, Brown MS The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982, 66:335-362.
65. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
66. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013, 128:2113-2120.
67. Guyton JR, Bays HE, Grundy SM, Jacobson TA An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014, 8:S72-S81.
68. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2541-2548.
69. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm (accessed Feb 20, 2016). https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469597.pdf.
70. Jacobson TA Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 2013, 88:1294-1311.
71. Nordestgaard BG, Tybjærg-Hansen A Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011, 22:113-122.
72. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
73. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
74. Kolski B, Tsimikas S Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol 2012, 23:560-568.
75. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014, 370:1809-1819.
76. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials. J Am Coll Cardiol 2014, 63:1278-1288.
77. Auer J, Berent R, Primus C PCSK9 inhibitors and cardiovascular events. N Engl J Med 2015, 373:773-775.
78. Stein EA, Raal FJ Targeting LDL: is lower better and is it safe?. Best Pract Res Clin Endocrinol Metab 2014, 28:309-324.
79. Everett BM, Mora S, Glynn RJ, MacFadyen J, Ridker PM Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol 2014, 114:1682-1689.
80. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005, 46:1411-1416.
81. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383:60-68.
82. Hooper AJ, Burnett JR, Watts GF Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circ Res 2015, 116:193-205.
83. Rader DJ, Kastelein JJP Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014, 129:1022-1032.
84. Blom D, Kastelein JJ, Larrey D, et al. Abstract 10818: Lomitapide Observational Worldwide Evaluation Registry (LOWER): one-year data. Circulation 2015, 132:A10818.
85. Sacks FM, Stanesa M, Hegele RA Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med 2014, 174:443-447.
86. Schonfeld G, Lin X, Yue P Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci 2005, 62:1372-1378.
87. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
88. van der Tuin SJL, Kuhnast S, Berbee JFP, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res 2015, 56:2085-2093.
89. Rader DJ, deGoma EM Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 2014, 65:385-403.
90. Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2015, 386:452-460.
91. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
92. Tardif J-C, Rhéaume É, Lemieux Perreault L-P, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015, 8:372-382.
93. Baxter JD, Webb P Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009, 8:308-320.
94. Bisgaier CL, Essenburg AD, Barnett BC, et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 1998, 39:17-30.
95. Differentiated product profile Gemphire Therapeutics, (accessed Feb 20, 2016). http://www.gemphire.com/products.php.
96. Isis Pharmaceuticals reports positive phase 1 data on Isis-ANGPTL3Rx Ionis Pharmaceuticals, (accessed Feb 20, 2016). http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2027634.
97. O'Riordan M PCSK9 inhibitors not cost-effective at current price: ICER review (accessed March 10, 2016). http://www.medscape.com/viewarticle/850715.
98. Jefferies 2014 Global Healthcare Conference (accessed March 10, 2016). http://www.jefferies.com/CMSFiles/Jefferies.com/files/Conferences/060214/Presentations/Aegerion%20Pharma.pdf.
99. Staton T Sanofi expands Kynamro marketing team to spark up sales (accessed March 10, 2016). http://www.fiercepharmamarketing.com/story/sanofi-expands-kynamro-marketing-team-spark-sales/2014-03-04.